(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75137 A1

(51) International Patent Classification[7]: C07D 405/14, 405/12, A61K 31/505, A61P 9/00

(21) International Application Number: PCT/EP00/04747

(22) International Filing Date: 23 May 2000 (23.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99201746.7 2 June 1999 (02.06.1999) EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DE BRUYN, Marcel, Frans, Leopold [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN EMELEN, Kristof [BE/BE]; Janssen Pharmaceutica N.V, Turnhoutseweg 30, B-2340 Beerse (BE). WIGERINCK, Piet, Tom, Bert, Paul [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VERSCHUEREN, Wim, Gaston [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: LEAPER, Lyn; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

[Continued on next page]

(54) Title: PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES


(I)



(a)


(C-1)


(C-2)


(C-3)


(C-4)


(C-5)

(57) Abstract: The present invention concerns compounds of formula (I), a stereochemically isomeric form thereof, an *N*-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -Z^1-Z^2- is a bivalent radical; R^1, R^2 and R^3 are each independently selected from hydrogen, C_{1-6}alkyl, hydroxy, halo and the like; or when R^1 and R^2 are on adjacent carbon atoms, R^1 and R^2 taken together may form a bivalent radical of formula; Alk is optionally substituted C_{1-6}alkanediyl; the bivalent radical (a) is a substituted piperidinyl, an optionally substituted pyrrolidinyl, homopiperidinyl, piperazinyl or tropyl; R^5 is a radical of formula (c-1), (c-2), (c-3), (c-4), (c-5) wherein n is 1 or 2; p^1 is 0, and p^2 is 1 or 2; or p^1 is 1 or 2, and p^2 is 0; X is oxygen, sulfur or =NR^9; Y is oxygen or sulfur; R^7 is hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, phenyl or phenylmethyl; R^8 is C_{1-6}alkyl, C_{3-6}cycloalkyl phenyl or phenylmethyl; R^9 is cyano, C_{1-6}alkyl, C_{3-6}cyclo-alkyl, C_{1-6}alkyloxycarbonyl or aminocarbonyl; R^{10} is hydrogen or C_{1-6}alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.

WO 00/75137 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.